CVVR in the News

Experimental AIDS vaccine protected half the monkeys as Human Tests Start - BloombergBusiness, July 2, 2015

“There’s more reason to be optimistic now than ever before, but we still have a long ways to go,” said Dan Barouch, a professor of medicine at Harvard Medical School who led the study. “Over the course of the HIV epidemic there have only been four concepts that have been tested in humans. We need more shots on goal.” See full article

 

Vaccine-Induced CD4 T Cells Lead to Adverse Effect in a Mouse Model of Infection - Science Daily, Jan 15, 2015

"A study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that a vaccine that elicits only CD4 T cells against a mouse model of a chronic viral infection results in an overwhelming -- and lethal -- inflammatory response. Reported in the January 16, 2015 issue of the journal Science, the new findings provide a cautionary tale for the development of vaccines aimed at eliciting robust CD4 T cell immunity against chronic infections, including HIV." See full article >

 

New AIDS Vaccine Comes in a Capsule - NBC News, Jan 13 2015

"Wanted: Volunteers to test an experimental new AIDS vaccine that is needle-free. The catch? You have to be willing to stay locked up in your room for 12 days. The new vaccine comes in a capsule and it's made using a common cold virus called an adenovirus, genetically engineered with a tiny piece of the AIDS virus. It's only a very early stage experiment, meant to show the vaccine is safe. However, if it is, it could be a start not only towards a much-needed vaccine against the AIDS virus, but needle-free vaccines against many different infections." See full article >

 

Supercharged Antibodies Fight HIV-related Virus in Monkeys - Nature News, October 2013

"Powerful antibodies against HIV show promise for bolstering antiviral therapies, studies in rhesus macaques suggest. Two papers published online today in Nature report the impact of antibody therapy on an HIV-related virus that is capable of infecting monkeys and was engineered to carry key portions of the genome of the human virus. Levels of that modified virus, called SHIV, plummeted after the macaques were infused with human antibodies isolated from HIV patients and selected for their potency against a broad array of HIV viruses." See full article >